Countries use various methods to control drug expenditures. Beyond simple negotiation, countries can also implement price controls or use WTO-authorized […]
Price controls and compulsory licensing give buyers more power … for a price. Read Post »
Investing and Clinical Trials PharmaGossip has an illuminating excerpt from The End of Medicine describing a method to invest in
There’s been a lot of press floating around lately about the push to develop a framework for biogeneric (or biosimilar,
I’ve been invited to join the editorial board of the nascent Open Biotechnology Journal. The Open Biotechnology Journal is a
Scientific Advances The MaRS Blog has a captivating story of Canada’s recent major diabetes discovery. The first discovery, in 1920,
This edition of the Carnival of Biotechnology features a number of posts on distressing industry trends, some enlightening patent discussion,
Guest content from John Avellanet, managing director of Cerulean Associates: As professionals affiliated with the biotechnology industry, we often forget
Harvard’s Gary Pisano has recently published a book titled “Science Business: The Promise, the Reality, and the Future of Biotech“
Lots of interesting developments since the last edition: Pfizer’s high-profile drug failiure, a new law against violent extremists, good news
Intellectual Property and Lawsuits Culture Dish has a post on a DNA sequencing technique patent dispute — Enzo biochem claims
Get new actionable insights and updates from BiotechBlog
